乌帕替尼维持治疗儿童溃疡性结肠炎:52周多中心研究
该回顾性多中心研究纳入105例儿童UC或IBD-U患者,评估乌帕替尼维持治疗52周的有效性与安全性。第52周71%达临床缓解,70%达无激素临床缓解,60%维持持续无激素缓解;50%出现不良事件,2例严重。
要点
- 乌帕替尼在难治性儿童UC中52周临床缓解率达71%,无激素缓解率70%
- 50%患儿出现不良事件,最常见为高脂血症、感染和痤疮,需权衡风险
- 98%患儿既往使用生物制剂,75%使用≥2种,提示该人群为难治性
核心结论
- 乌帕替尼对难治性儿童UC和IBD-U是有效的诱导和维持治疗,但需权衡不良事件风险。
研究设计与样本
- 回顾性多中心研究,纳入35个ESPGHAN Porto组附属中心的105例儿童(95例UC,10例IBD-U),平均年龄14.6±3.3岁,随访52周。
主要发现
- 第8周61例(58%)达临床缓解,53例(51%)达无激素临床缓解;第52周75例(71%)达临床缓解,73例(70%)达无激素临床缓解。
- 第52周持续无激素缓解63例(60%),无激素缓解且CRP正常者占56%,无激素缓解且粪钙卫蛋白<150 mcg/g者占38%。
- 52例(50%)发生不良事件,其中2例严重(阑尾神经内分泌肿瘤和巨细胞病毒结肠炎);最常见为高脂血症(20例)、感染(18例)和痤疮(14例)。
临床怎么用
- 对于既往生物制剂治疗失败的难治性儿童UC或IBD-U,乌帕替尼可作为维持治疗选择,但需监测不良事件。
局限性
- 回顾性研究设计,样本量有限,缺乏对照组,可能影响因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as a maintenance therapy in pediatric UC. METHODS: Children treated with upadacitinib for maintenance of remission of active UC or IBD-U from 35 centers affiliated with the Porto group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) were enrolled in this retrospective study. Data on demographic, clinical, laboratory, endoscopic, imaging, and adverse events (AEs) were recorded over 52 weeks of follow-up. RESULTS: A total of 105 children were included (95 with UC and 10 with IBD-U; mean age, 14.6 ± 3.3 years). Prior to upadacitinib, 103 of 105 children (98%) were treated with biologic therapies and 79 (75%) with ≥2 biologics. Clinical remission and corticosteroid-free clinical remission (CFR) were observed after 8 weeks in 61 (58%) and 53 (51%) children, respectively. By week 52, 75 children (71%) achieved clinical remission and 73 (70%) achieved CFR. Sustained CFR was recorded in 63 children (60%). CFR with normal C-reactive protein was observed in 56% of children, and CFR with fecal calprotectin levels <150 mcg/g was observed in 38%, by week 52. Fifty-two children (50%) experienced AEs, 2 of which were serious (an appendiceal neuroendocrine tumor and cytomegalovirus colitis). The most frequent AEs were hyperlipidemia (n = 20), infections (n = 18), and acne (n = 14). CONCLUSIONS: Upadacitinib is an effective induction and maintenance therapy for refractory pediatric UC and IBD-U. Effectiveness should be weighed against the potential risks of AEs.
引用
- Yerushalmy-Feler A, Spencer EA, Dubinsky MC, et al. Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. Clin Gastroenterol Hepatol. 2026. PMID: 41713826. doi:10.1016/j.cgh.2026.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。